Juvenile Idiopathic Arthritis

Safety of ADA in Pediatric Polyarticular JIA, ERA

WASHINGTON, DC — There was no change in safety profile for adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis (ERA), psoriasis (Ps), and Crohn’s disease (CD), a recent analysis showed. The research was presented at the American College of Rheumatology (ACR) 2016 Annual Meeting. Gerd Horneff, MD, from the Asklepios Kliniken GmbH…

Next post in General Rheumatology